ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care
Multi-year partnership to advance the use of next-generation sequencing for decentralized oncology testing, to bring improved insights to patients with breast cancer globally IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 10, 2022 – Agendia, Read More
Agendia Appoints Suja Chandrasekaran and Scott Mendel to Board of Directors, Strengthening Advisory Group to Support Company Momentum
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 6, 2022 – Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced the appointment of healthcare industry veterans Suja Chandrasekaran, MS Read More
Agendia Spotlight Poster at SABCS 2021 Confirms Utility of BluePrint as Biomarker Subtyping Test to Guide Neoadjuvant Chemotherapy Decisions
Additional research from the real-world FLEX Registry focuses on age effect and lymph node status for patients with breast cancer IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 10, 2021 – Agendia, Inc., a world Read More
Analysis Presented at SABCS 2021 Confirms MammaPrint and BluePrint Predict Outcomes Following Neoadjuvant Chemotherapy
Data signal importance of serial genomic testing in order to appropriately adjust breast cancer treatment plans IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 9, 2021 – Agendia, Inc., a world leader in precision oncology Read More